Introduction & Objectives: Oral semaglutide, the only oral glucagon-like peptide-1 receptor agonist (GLP‑1RA) available for the treatment of T2D, is efficacious and has a safety profile consistent with the GLP-1RA class. This post hoc analysis of Chinese patients with T2D included in the PIONEER 11 and 12 trials investigates the efficacy of oral semaglutide vs comparators by different baseline (BL) characteristics.
Methods: Chinese patients with T2D (HbA1c 7.0-10.0% in PIONEER 11; 7.0-10.5% in PIONEER 12), aged ≥18 years, were randomized to once-daily oral semaglutide 3, 7 or 14 mg or comparator (placebo [PIONEER 11] or sitagliptin 100 mg [PIONEER 12]). Estimated change from BL in HbA1c and body weight were analyzed at week 26 by subgroups of BL characteristics, including age, GI disease and HbA1c.
Results: In total, 390 (PIONEER 11) and 1,084 (PIONEER 12) Chinese patients were evaluated. At baseline, mean HbA1c and body weight values were similar across most BL subgroups (data not shown). Overall, greater reductions in HbA1c and body weight were seen with oral semaglutide vs placebo or sitagliptin across the BL subgroups (Table 1).
Conclusion: Significant reductions in HbA1c and body weight were observed with oral semaglutide across BL subgroups, including age, GI disease and HbA1c,vs comparator.
L. Ji: None. G. Yuan: None. J. Liu: None. B. Zhang: None. W. Liu: Employee; Novo Nordisk A/S. Z. Shen: Employee; Novo Nordisk A/S. Stock/Shareholder; Novo Nordisk A/S.
